Andere talen ViroGates A/S

Aandelen

VIRO

DK0061030574

Vertraagde tijd Nasdaq Copenhagen Andere beurzen 13:32:21 16-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,1 ^DKK	-5,43%		-10,29%	+1,33%

02/05	ViroGates A/S rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
15/04	Virogates A/S kondigt het resultaat aan van de Q-Submission Filing voor Sobi®? Turbi Latex bij de Amerikaanse Food and Drug Administration	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ViroGates A/S : Interim Report, Q1 2024	02/05
ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 2023	02/05
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Resolutions from the Annual General Meeting of ViroGates A/S	25/04
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA	15/04
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	15/04
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024	10/04
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage	21/03
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S	21/12
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	21/12
ViroGates publishes its financial calendar for 2024	21/12
ViroGates announces financial guidance for 2024	21/12
ViroGates A/S Provides Earnings Guidance for the Year 2024	21/12
ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered	19/12
ViroGates announces the outcome of its rights issue	15/12
ViroGates A/S : Most interesting suPAR studies of 2023	08/12
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	07/12
ViroGates A/S : Clinical role of suPAR in the prognosis of patients in the emergency setting and its influence on risk stratification	06/12
The subscription period in ViroGates’ rights issue begins today	30/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ViroGates A/S

Aandelen

VIRO

DK0061030574

Andere talen

Filters